Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
2081-2100 of 2,251 trials

SGLT-2 Inhibitors for Elderly Patients with Type 2 Diabetes

We are comparing different SGLT-2 inhibitors to see which helps elderly patients manage their blood sugar levels safely. The study looks at effectiveness and potential side effects over time.

Type 2 DiabetesMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesDiabetologyEndocrinology

Virus-Specific T-Cell Therapy for Resistant Viral Infections Post-Stem Cell Transplant

We are studying the safety of using specially selected T-cells to treat young patients with viral infections like Adenovirus and Cytomegalovirus after a stem cell transplant. The trial also aims to see how well this treatment controls symptoms related to these infections.

Graft Infection1-2 yearsSafety phase (I)No PlaceboHematologyInfectious Diseases

High Blood Pressure: Metyrapone for Adrenal Tumors

We are studying if adding Metyrapone helps patients with high blood pressure and adrenal tumors manage their condition better. This trial aims to improve blood pressure control in those with subclinical Cushing's syndrome.

Adrenal Incidentalomas and Mild Cushing’s Syndrome>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesCardiologyEndocrinology

Bladder Cancer: New Treatment Combination Study

We are investigating a new treatment combining chemotherapy and immunotherapy with radiotherapy for patients with non-metastatic muscle invasive bladder cancer. The goal is to see if this approach improves survival and quality of life after surgery.

Non-Metastatic Muscle Invasive Bladder Cancer1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesOncologyUrology

Pancreatic Cancer: Nabpaclitaxel Chemotherapy Study

We are studying a new combination of chemotherapy treatments for patients with pancreatic cancer that has spread to the abdominal lining. The goal is to see if this approach can help shrink tumors and improve survival.

Pancreatic Cancer with Peritoneal MetastasesEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Chronic Graft-Versus-Host Disease: Axatilimab Treatment Study

We are comparing a new treatment called axatilimab to the best available therapy for patients with chronic graft-versus-host disease who have not responded to previous treatments. The goal is to see if axatilimab is more effective and safer.

Chronic Graft-Versus-Host Disease>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Colorectal Cancer: Galunisertib and Capecitabine Study

We are investigating a new drug combination for patients with advanced colorectal cancer that hasn't responded to chemotherapy. The goal is to learn more about its safety and effectiveness in treating this condition.

Metastatic Colorectal CancerSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Advanced Colorectal Cancer: FOLFIRI and Cetuximab Treatment

We are studying whether a combination of FOLFIRI and Cetuximab is effective for patients with advanced colorectal cancer who have specific genetic markers. This research aims to improve first-line treatment options for these patients.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

X-ALD: Pramipexole for Leg Symptoms

We are investigating whether pramipexole can help reduce restless leg symptoms in women with X-linked Adrenoleukodystrophy. This study aims to improve their sleep and walking performance.

X-linked AdrenoleukodystrophyRestless Legs Syndrome3-6 monthsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurology

Advanced Clear-Cell Renal Carcinoma: Digital Monitoring with Cabozantinib and Nivolumab

We are studying how digital tracking of symptoms can help adjust treatments for patients with advanced clear-cell renal carcinoma receiving Cabozantinib and Nivolumab. This may improve their overall health and quality of life during treatment.

Kidney Cancer>2 yearsMonitoring phase (IV)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicineOncologyUrology

Ulcerative Colitis: Comparing Risankizumab and Vedolizumab

We are studying whether risankizumab is more effective and safe than vedolizumab for adults with moderate to severe ulcerative colitis who have not yet received targeted treatments.

Ulcerative Colitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Locally Advanced Rectal Cancer: NeoAspMet Trial

We are studying whether adding aspirin or metformin to standard chemotherapy improves tumor response in patients with locally advanced rectal cancer. This trial aims to see if these treatments can lead to better outcomes compared to standard care.

Locally Advanced Rectal CancerEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Pleural Mesothelioma: Ivonescimab Treatment Study

We are evaluating ivonescimab for patients with relapsing pleural mesothelioma who have already been treated with immunotherapy and chemotherapy. The study aims to assess its safety and effectiveness as a potential new treatment option.

Pleural Mesothelioma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Chronic Hepatitis Delta: Brelovitug Treatment Study

We are studying a new medication, brelovitug, for people with chronic hepatitis delta infection. The trial aims to see if it works better than waiting for treatment and to evaluate its safety.

Hepatitis D>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatology

Basal Cell Carcinoma: Electrochemotherapy vs. Radiotherapy

We are comparing a new treatment called electrochemotherapy with standard radiotherapy for small basal cell carcinomas. The study will also assess side effects, appearance after treatment, and patient satisfaction.

Basal Cell Carcinoma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesDermatologyOncology

Gastric Cancer: Pre-operative Treatment with Capecitabine and Atezolizumab

We are studying a combination of chemotherapy and immunotherapy for patients with resectable gastric and GE-junction cancer. The goal is to see if this treatment is safe and effective in shrinking tumors before surgery.

Gastric Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

TryptoBPH: Tryptophan for Benign Prostatic Hyperplasia

We are studying whether tryptophan can improve urinary symptoms in men with benign prostatic hyperplasia. The trial will also look at its effects on prostate size and quality of life.

Benign Prostatic Hyperplasia6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineUrology

Neuroblastoma: Innovative Stem Cell Transplant and Immunotherapy

We are studying a new stem cell transplant method followed by immunotherapy for children with relapsed or resistant high-risk neuroblastoma. This trial aims to evaluate the safety and effectiveness of this approach in improving treatment outcomes.

Neuroblastoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

High-Risk Thyroid Cancer: Neoadjuvant Pembrolizumab Study

We are studying the effects of pembrolizumab as a pre-surgery treatment for patients with high-risk thyroid cancers. The goal is to see if it improves outcomes and understand how the body responds to this therapy.

Thyroid CancerEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Follicular Lymphoma: Golcadomide with Rituximab Study

We are comparing a new treatment combination to standard options for patients with relapsed or refractory follicular lymphoma. The study aims to see if this combination improves survival and quality of life.

Follicular LymphomaRelapsed/Refractory Follicular Lymphoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology